文献速递脊柱关节炎

12项银屑病关节炎疾病影响量表的效度与评分解读:两项比美吉珠单抗治疗银屑病关节炎3期试验汇总数据的分析

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis.
PubMed 文献 · RMD Open · 2024-01-31

基于两项比美吉珠单抗治疗活动性银屑病关节炎3期试验至第16周共1252例患者数据,评估PsAID-12量表的心理测量学性能并估计评分变化阈值及症状/影响严重程度阈值。结果显示该量表信效度良好,总表改善阈值为1.5–2分,条目为2或3分。

要点

  • PsAID-12总表基线均值(SD)为4.19(1.94),内部一致性信度Cronbach α为0.95。
  • 重测信度ICC≥0.70,反应度可接受(多数评分相关系数≥0.30)。
  • 总表改善阈值为1.5–2分,条目评分改善阈值为2或3分。

核心结论

  • PsAID-12在活动性银屑病关节炎大样本中显示出稳健的心理测量学性能,支持其作为该人群适用的患者报告结局工具,并推导出评分解读阈值。

研究设计与样本

  • 汇总两项比美吉珠单抗随机对照试验(BE OPTIMAL,NCT03895203;BE COMPLETE,NCT03896581)至第16周的数据,纳入1252例活动性银屑病关节炎患者,评估结构效度、已知组效度、信度及反应度,并估计阈值。

主要发现

  • 基线PsAID-12总表均值(SD)为4.19(1.94)。
  • 结构效度良好(与其他患者报告结局相关),已知组效度良好(基于最小疾病活动度指数、银屑病关节炎疾病活动指数及银屑病关节炎疾病活动评分)。
  • 内部一致性信度Cronbach α为0.95,重测信度ICC≥0.70;反应度可接受(多数评分相关系数≥0.30)。

关键数值与推荐

  • PsAID-12总表临床有意义改善阈值为1.5–2分,条目评分改善阈值为2或3分。
  • 多数PsAID-12条目可推导出不同症状/影响严重程度的阈值。
  • 改善阈值通过锚定法和分布法估计,症状/影响严重程度阈值通过受试者工作特征曲线分析估计。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate psychometric performance of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) total and individual item scores in patients with psoriatic arthritis (PsA) and to estimate score change thresholds and scores corresponding to different levels of symptom/impact severity. METHODS: Data up to week 16 from 1252 patients with active PsA enrolled in two randomised controlled trials of bimekizumab (BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581)) were used to assess construct validity (correlations with other patient-reported outcomes), known-groups validity (based on Minimal Disease Activity index, Disease Activity Index for Psoriatic Arthritis and Psoriatic Arthritis Disease Activity Score), reliability (Cronbach's alpha and intraclass correlation coefficients (ICCs)) and responsiveness (sensitivity to change). Clinically meaningful within-patient improvement thresholds were estimated by anchor-based and distribution-based analyses, and symptom/impact severity thresholds were estimated by receiver operating characteristic curve analyses. RESULTS: The mean (SD) PsAID-12 total score at baseline was 4.19 (1.94). PsAID-12 scores demonstrated good convergent validity and good known-groups validity. Internal consistency reliability (Cronbach's alpha 0.95) and test-retest reliability (ICC ≥ 0.70) were also good. Responsiveness was acceptable (correlations ≥0.30 for most scores). Improvement thresholds were estimated at 1.5-2 points for the PsAID-12 total score and 2 or 3 points for item scores. Thresholds for different levels of symptom/impact severity could be derived for most PsAID-12 items. CONCLUSIONS: The PsAID-12 demonstrated robust psychometric properties in a large sample of patients with active PsA, supporting its use as a fit-for-purpose patient-reported outcome in this population. Furthermore, thresholds for score interpretation were derived.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Gossec L, Orbai AM, Coates LC, et al. Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. RMD Open. 2024. PMID: 38296802. doi:10.1136/rmdopen-2023-003548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。